Breaking Down Barriers: Why Biosimilars Face Resistance in the US Market

Despite a boom of new, cost-efficient options for chronic conditions, prescriber and patient concern over clinical benefit persists.

Related Keywords

United Kingdom ,United States ,New Zealand ,Pritchettj Biosimilars ,Jessica Ooman ,Juliana Reed ,Russelld Cohen ,Adalimumab Biosimilar ,Chiara Gasteiger ,Fresenius Kabi ,University Of Chicago Medicine ,Association For Accessible Medicines ,Institute For Human Data Science ,Biosimilars Forum ,Drug Administration ,Body Lab At Stanford University ,Chicago Medicine ,Medical Affairs ,Body Lab ,Stanford University ,Biosimilar Medicines Savings ,Accessed December ,Human Data ,Drug Evaluation ,Interchangeable Biosimilar ,Patient Experiences ,Mandatory Nationwide Transition ,Biosimilars ,Market ,Us ,Adalimumab ,Humira ,Fda ,Recap ,2023 ,This Year In Medicine ,